Contrasting Demant A/S (OTCMKTS:WILYY) & ReWalk Robotics (NASDAQ:LFWD)
Demant A/S (OTCMKTS:WILYY – Get Free Report) and ReWalk Robotics (NASDAQ:LFWD – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Volatility & Risk
Demant A/S has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
Profitability
This table compares Demant A/S and ReWalk Robotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Demant A/S | N/A | N/A | N/A |
| ReWalk Robotics | -159.76% | -28.19% | -23.29% |
Institutional & Insider Ownership
26.8% of ReWalk Robotics shares are owned by institutional investors. 2.1% of ReWalk Robotics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Demant A/S and ReWalk Robotics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Demant A/S | $3.26 billion | 3.24 | $260.63 million | N/A | N/A |
| ReWalk Robotics | $13.85 million | 3.29 | -$22.13 million | ($2.87) | -1.87 |
Demant A/S has higher revenue and earnings than ReWalk Robotics.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Demant A/S and ReWalk Robotics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Demant A/S | 0 | 1 | 3 | 0 | 2.75 |
| ReWalk Robotics | 0 | 0 | 1 | 0 | 3.00 |
ReWalk Robotics has a consensus target price of $21.00, suggesting a potential upside of 291.79%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, analysts plainly believe ReWalk Robotics is more favorable than Demant A/S.
About Demant A/S
Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Receive News & Ratings for Demant A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Demant A/S and related companies with MarketBeat.com’s FREE daily email newsletter.
